GENETICS AND ENVIRONMENTAL FACTORS OF GLAUCOMA & MYOPIA
Professor David Mackey AO,
Professor of Ophthalmology
The Lions Eye Institute,
University of Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor David Mackey, AO is a clinician, scientist and academic. He is Professor of Ophthalmology at UWA and was the Lions Eye Institute’s Managing Director from 2009 until 2018.
A University of Tasmania medical graduate, Professor Mackey completed his ophthalmology training at the Royal Victorian Eye and Ear Hospital in Melbourne. After an MD thesis on Leber Hereditary Optic Neuropathy at the University of Melbourne, he completed fellowships in the US and UK in genetic eye diseases.
A renowned international researcher on the genetics of eye disease, Professor Mackey leads the Lions Eye Institute’s Genetics and Epidemiology research group, which pursues multiple projects aimed at understanding how genes and environment interact to influence an individual’s risk of eye disease.
Professor Mackey collaborates with researchers worldwide. He is a lead investigator in the International Glaucoma Genetics Consortium (IGCC) and the Consortium for Refractive Error and Myopia (CREAM). In the 1990s he coordinated an international consortium across eight countries to establish the frequency of Leber Hereditary Optic Neuropathy (LHON) mutations.
In Australia, he initiated the Glaucoma Inheritance Study in Tasmania – creating one of the largest glaucoma biobanks in the world and contributing to the discovery of more than a dozen genes associated with Mendelian genetic eye disease.
The Twins Eye Study in Tasmania and Brisbane, the Norfolk Island Eye Study, the eye component of the WA Pregnancy (Raine) Cohort, Busselton Healthy Aging Study are his other major projects.
Professor Mackey’s original research, over more than 30 years into the genetics of glaucoma and in the fields of optic atrophy and congenital cataract, has received constant professional accolades, attracted ongoing research funding and led to his publication of more than 400 peer-reviewed papers.
In 2019, he was made an Officer (AO) in the General Division of the Order of Australia for “distinguished service to medicine, and to medical education, in the field of ophthalmology, as a clinician-scientist and academic”.
Source: Lions Eye Institute website
https://orcid.org/0000-0001-7914-4709
-
Using Gut Microbes to Reduce Blood Pressure
Professor Francine Marques is an National Health and Medical Research Council Emerging Leader, Viertel Charitable Foundation, and National Heart Foundation Fellow.
She leads the Hypertension Research Laboratory at Monash University and has published more than 120 peer-reviewed papers in journals such as Nature Reviews Cardiology, Nature Medicine, Nature Cardiovascular Research, and Circulation.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
